Is Everest Medicines Limited stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Everest Medicines Limited 10 years ago, but if you had invested on Friday 9th of October 2020 when the price was HKD72.75, you would have made a loss of HKD-49.25 per share or -67.70%
Yes, the average daily trading liquidity for Everest Medicines Limited is HKD1.54 million. You should therefore be able to get in and out of your positions relatively fast.
Everest Medicines Limited has little of the business financed by loans. This puts the company at lower risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Everest Medicines Limited to be medium [0.7 of 1]
US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.